Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients.

Campos-Varela I, Esteban JI, Bes M, Dopazo C, Allende H, Rodríguez-Frías F, Salcedo MT, Sauleda S, Charco R, Guardia J, Esteban R, Castells L.

Ann Hepatol. 2014 Mar-Apr;13(2):219-30.

2.

Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1.

Campos-Varela I, Esteban JI, Bes M, Caralt M, Allende H, Rodríguez-Frías F, Salcedo MT, Sauleda S, Charco R, Guardia J, Esteban R, Castells L.

J Viral Hepat. 2014 Oct;21(10):e118-28. doi: 10.1111/jvh.12246. Epub 2014 Mar 12.

PMID:
24620835
3.

Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation.

Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T.

PLoS One. 2013;8(3):e58380. doi: 10.1371/journal.pone.0058380. Epub 2013 Mar 7. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/1601274b-def0-4970-8e61-62e657c2d1ae.

4.

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.

Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83. doi: 10.1097/MEG.0b013e3282f762f8.

PMID:
18617783
5.

[Old donors in liver transplantation for chronic hepatitis C].

Aguilera V, Ponce M, Berenguer M, Moreno R, Rayón JM, Sanjuán F, Prieto M, Mir J.

Rev Esp Enferm Dig. 2007 Oct;99(10):581-7. Spanish.

6.

Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients.

Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB.

Transpl Int. 2013 Jan;26(1):42-9. doi: 10.1111/j.1432-2277.2012.01571.x. Epub 2012 Nov 8.

7.

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.

Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.

Liver Transpl. 2007 Aug;13(8):1100-8.

8.

Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.

García-Reyne A, Lumbreras C, Fernández I, Colina F, Abradelo M, Magan P, San-Juan R, Manrique A, López-Medrano F, Fuertes A, Lizasoain M, Moreno E, Aguado JM.

Transpl Infect Dis. 2013 Aug;15(4):405-15. doi: 10.1111/tid.12097. Epub 2013 Jun 3.

PMID:
23725370
9.

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.

Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D.

Liver Transpl. 2008 Dec;14(12):1766-77. doi: 10.1002/lt.21635.

10.

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2004 Feb;10(2):199-207.

11.

The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.

Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ, Ito T, Irving WL.

J Viral Hepat. 2014 Mar;21(3):208-15. doi: 10.1111/jvh.12132. Epub 2013 Aug 1.

PMID:
24438682
12.

Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.

Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group.

Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30.

13.

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

J Viral Hepat. 2014 Aug;21(8):568-77. doi: 10.1111/jvh.12185. Epub 2013 Oct 10.

PMID:
24118177
14.

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M.

Am J Transplant. 2008 Mar;8(3):679-87. doi: 10.1111/j.1600-6143.2007.02126.x.

15.
16.

Impact of antiviral treatment on survival in HCV-positive liver recipients.

Wawrzynowicz-Syczewska M, Zeair S, Andruszkiewicz A, Bartoszewicz K, Sławiński J, Laurans Ł, Jurczyk K, Karpińska E, Socha Ł, Duczkowska M, Parczewski M.

Ann Transplant. 2014 Jul 30;19:367-72. doi: 10.12659/AOT.890612.

17.

The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.

Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR.

Transplantation. 2012 Jul 27;94(2):197-203. doi: 10.1097/TP.0b013e3182547551.

PMID:
22766768
18.

Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.

Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.

Liver Transpl. 2009 Jul;15(7):782-9. doi: 10.1002/lt.21760.

19.

Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.

Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M; AISF RECOLT-C group study.

Transpl Int. 2012 Apr;25(4):448-54. doi: 10.1111/j.1432-2277.2012.01440.x. Epub 2012 Feb 21.

20.

Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

PLoS One. 2013 Nov 12;8(11):e80528. doi: 10.1371/journal.pone.0080528. eCollection 2013.

Supplemental Content

Support Center